NewsRoom Articles - Page 116 of 207

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

MondayFeb 14, 2022 9:30 am

UK Study Shows Dementia Risk Doubles for People with More Than One Chronic Disease

Dementia is a debilitating condition that affects individuals in their old age. The disease impacts around 57 million people globally, with experts predicting that by 2050, about 153 million individuals will have developed dementia. To compound matters even more, a new study has found that the risk of a middle-aged individual developing dementia heightens significantly, especially if they suffer from two or more chronic health issues in middle age. This is known as multimorbidity, which is the presence of two or more chronic diseases from a list of 13 diseases, including cancer, arthritis, liver disease, depression, stroke, heart failure, diabetes…

MondayFeb 14, 2022 9:30 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD's sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022,…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

FridayFeb 11, 2022 9:30 am

New York Eases Access to Medical Marijuana

Earlier this year, the state of New York gave permission to physicians to prescribe medical marijuana for a myriad of conditions. These changes represent a huge shift in the state’s medical cannabis program, which was at one point among the most restrictive in the country. The state is focused on establishing its legal recreational marijuana market, with its Office of Cannabis Management allowing dispensaries to begin selling whole cannabis buds for smoking, expanding ranks of providers and proposing rules for patients who would like to cultivate their own cannabis. Many expect the state’s soon-to-be established adult-use marijuana market to become…

ThursdayFeb 10, 2022 9:30 am

What You Should Know about Seasonal Depression

Seasonal depression, or seasonal affective disorder, is a form of depression that occurs at a similar time every year. It typically comes during the winter and fall seasons, which is why it is important to be aware of correlated mental health conditions as winter rages on. Estimates show that roughly 5% of individuals in the United States are affected by seasonal depression, with data from U Health also showing that about 14% of adults in the country are impacted by milder versions of seasonal depression as well as other mood disorders. Chief of the Adult Psychiatry Division at the University…

WednesdayFeb 09, 2022 9:30 am

Diabetes Fatalities in US Top 100,000 for Second Consecutive Year

Diabetes was the seventh-leading cause of death in the United States in 2019, claiming the lives of more than 87,000 individuals. However, recently publicized data shows that more than 100,000 individuals in the U.S. succumbed to diabetes last year. These new figures come as the National Clinical Care Commission calls for Congress to improve diabetes care and prevention, having given recommendations to stop relying solely on medical interventions. A report that was released last month urges that broader policy changes be made in an effort to contain the diabetes epidemic. These changes include expanding access to affordable housing, imposing taxes…

WednesdayFeb 09, 2022 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate through the launch of its proprietary body worn continuous glucose sensor in both the diabetes sector and consumer healthcare sector. The company’s flagship sugarBEAT(R) device provides diabetic and pre-diabetic patients with the ability…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

TuesdayFeb 08, 2022 9:30 am

COVID-19 Stress May Cause Onset of PTSD

New research has discovered that traumatic stress associated with the coronavirus may be used to predict post-traumatic stress disorder. The researchers found a link between PTSD and COVID traumatic stress, noting that it was stronger in people who had repeatedly experienced past trauma. In their report, the researchers noted that their findings were true across almost all racial groups, excluding Asian Americans. The lead author of the study, Professor Jeff Ashby, has specialized in counseling and psychological services. He stated that despite many individuals being insulated from economic hardship and deaths associated with the pandemic, there was a universal experience…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

UK Study Shows Dementia Risk Doubles for People with More Than One Chronic Disease

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

New York Eases Access to Medical Marijuana

What You Should Know about Seasonal Depression

Diabetes Fatalities in US Top 100,000 for Second Consecutive Year

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

COVID-19 Stress May Cause Onset of PTSD

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search